CD8A and cancer: Type 1 Conventional DCs (cDC1s) have an optimal ability to cross-present tumor antigens to CD8+ T cells and produce high amounts of IL-12, making them potent anti-tumor cells [56], and the accumulation of cDC1s in the TME is of good prognosis in many cancers [57].